Epeius Pharma News
1 article
growth-positive
FutuRx, together with Ramot at Tel-Aviv University and Glasgow University, Launches Epeius pharma to develop treatments for complex neurological diseases
FutuRx, Israels leading biopharmaceutical incubator, has launched a new portfolio company called Epeius Pharma. Epeius Pharma focuses on developing next-generation biological vehicles for the delivery of therapeutic proteins into the central nervous system. The company aims to overcome the challenges posed by the blood-brain barrier, which limits the delivery of therapeutic agents to the brain. Epeius Pharma will utilize a novel biological platform and apply cell and gene therapy approaches to enable the introduction of therapeutic proteins into the CNS. The company plans to develop the drug delivery platform and combine it with several therapeutic candidates for clinical testing and validation. Epeius Pharma was founded based on joint research efforts from Tel Aviv University and the University of Glasgow. FutuRx, as an incubator, provides funding, infrastructure, expertise, and mentorship to translate academic research into clinical treatments.
Partners